The online community for biotechnology industry of Switzerland.

SuisseBio has seen steady growth since 2004 and is expected to continue to expand. The Swiss biopharmaceutical market’s strength lies in the ability to carry products to the final stage of development. Switzerland ranks second in the number of pipelines in all phases according to Ernst & Young. Although Switzerland is a smaller country, its success has placed this Hotbed in the company of the world’s most successful biotechnology markets.

Join the World Discussion Forum

Click here to Search Jobs

Hotbed News
Biotech Layoffs Often Go Hand-In-Hand With CEO Pay Raises Monday, September 29, 2014
BioPharm Executive: Building Biotech's Next Boom Thursday, September 25, 2014
FDA Says Novartis AG (NVS), Roche (RHHBY)'s Asthma Drug Xolair Raises Risk Of Heart, Brain Problems Tuesday, September 30, 2014
Roche (RHHBY) To Invest $535M, Create 3,500 Jobs At New Swiss IT Site Friday, September 19, 2014
Analyst: Novartis AG (NVS), Celgene (CELG) Might Go Toe-to-Toe Over Psoriasis Drugs Friday, September 26, 2014
Helsinn Group Release: Pivotal Phase 3 Trial Data For Anamorelin In ROMANA 1 And 2 Studies In Non-Small Cell Lung Cancer Patients With Anorexia-Cachexia Shows Significant Increase In Lean Body Mass, Body Weight And Improved Symptoms Monday, September 29, 2014
Cubist Pharmaceuticals, Inc. (CBST) Opens Global HQ; To Invest Approximately $400 Million On Antibiotic R&D Monday, September 22, 2014
Novartis AG (NVS), Roche (RHHBY) Cry Foul On New Swiss Pricing System Wednesday, September 17, 2014
Swiss Biotech Firm Molecular Partners AG Plans $134 Million IPO Wednesday, September 24, 2014
Ex-Genentech (RHHBY) Boss Resigns From Roche (RHHBY)'s Board; Fears Conflict Of Interest With New CEO Post At Google Inc.'s Calico Monday, September 08, 2014
12345678910